Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NX-1607 Phase 1 Study in Advanced Malignancies
NCT05107674Phase 1Recruiting
- Sponsor
- Nurix Therapeutics
- Start
- Sep 2021
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of NX-1607 in Epithelial Ovarian Cancer (EOC), gastric cancer (GC), gastroesophageal junction cancer and 10 more (12 arms), sponsored by Nurix Therapeutics. Primary endpoints: Incidence of treatment-emergent adverse events at 16 months, Incidence of immune-related AEs, all deaths, and dose-limiting toxicities at 2 Years and 1 more. Started Sep 2021; status: recruiting.
02
Drugs
NX-1607
03
Conditions
Epithelial Ovarian Cancer (EOC)gastric cancer (GC)gastroesophageal junction cancerhead and neck squamous cell carcinoma (HNSCC)melanoma
Beyond the preview
Go deeper on NCT05107674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05107674.